PTC Therapeutics PTCT Translarna — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's translarna — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's translarna — revenue?
- PTC Therapeutics (PTCT) reported translarna — revenue of $58.98M in Q1 2026.
- How has PTC Therapeutics's translarna — revenue changed year-over-year?
- PTC Therapeutics's translarna — revenue decreased by 31.5% year-over-year, from $86.15M to $58.98M.
- What is the long-term trend for PTC Therapeutics's translarna — revenue?
- Over 2 years (2021 to 2025), PTC Therapeutics's translarna — revenue has grown at a -35.4% compound annual growth rate (CAGR), from $236M to -$98.63M.
- What does translarna — revenue mean?
- This metric represents the net revenue recognized from the sale of the specific therapeutic product after adjusting for variable considerations such as rebates, discounts, and returns. It reflects the core commercial performance of the product line by excluding taxes collected from customers on behalf of government authorities. This figure is a primary indicator of the product's market adoption and commercial viability.